Impact of Computer-aided Optical Diagnosis (CAD) in Predicting Histology of Diminutive Rectosigmoid Polyps: a Multicenter Prospective Trial (ABC Study).

Sponsor
Valduce Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04607083
Collaborator
(none)
1,134
1
5.2
217.1

Study Details

Study Description

Brief Summary

Recently, a CNN-based artificial intelligence (AI) system for polyp characterization has been developed by Fujifilm Co., Tokyo, Japan. It works in conjunction with BLI system. In the present study we prospectively evaluate whether the evaluation of the endoscopist combined with the CAD system output achieve > 90% accuracy in characterization (i.e. as adenomas or non-adenomas) of diminutive rectosigmoid polyps having histopathology as reference standard. Consecutive adult outpatients undergoing elective colonoscopy, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected are included. During endoscopic procedures all polyps identified by the endoscopist are documented for size, location and morphology. All diminutive polyps are characterized by a three sequential steps process: I) endoscopist prediction: the endoscopist evaluates the polyp by using BLI through the BASIC classification; the confidence level (high vs. low) in histology prediction is recorded; II) AI prediction: the AI system is switched on and the output of the automatic evaluation is recorded; this outcome is rated as stable or unstable, depending of the consistency over time of the outcome; III) combined prediction: a final classification is provided by endoscopist in light of the results of the first and of the second step; the confidence level is recorded. All polyps are resected and retrieved in separate jars and sent for pathology assessment. Only polyps characterized with high confidence will be included in the per-polyp analysis; the high-confidence characterization rate will be also calculated; the rate of polyps characterized with a CAD stable outcome will be calculated. Operative characteristics (sensitivity, specificity, positive and negative predictive value and accuracy) in distinguishing adenomatous from non-adenomatous polyps, evaluated with high confidence, will be calculated for each diminutive polyp and for each diminutive rectosigmoid polyp, having histopathology report as reference standard. The post-polypectomy surveillance intervals will be calculated on the basis of polyp histology (reference standard) in all patients according to both USMSTF and ESGE guidelines.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Polyp carachterization by combing endoscopist evaluation and Ai output

Study Design

Study Type:
Observational
Actual Enrollment :
1134 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Impact of Computer-aided Optical Diagnosis (CAD) in Predicting Histology of Diminutive Rectosigmoid Polyps: a Multicenter Prospective Trial (Artificial Intelligence BLI Characterization - ABC Study).
Actual Study Start Date :
Oct 22, 2020
Actual Primary Completion Date :
Feb 27, 2021
Actual Study Completion Date :
Mar 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Patients with at least one diminutive rectosigmoid polyp

Consecutive adult (>18 years) outpatients undergoing elective colonoscopy, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected. Exclusion criteria: patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer patients with inadequate bowel preparation patients in which caecal intubation was not achieved or scheduled for partial examinations polyps could not be resected due to ongoing anticoagulation preventing resection and pathologic assessment patients undergoing urgent colonoscopy.

Diagnostic Test: Polyp carachterization by combing endoscopist evaluation and Ai output
A polyp characterization (adenoma vs. non adenoma) is provided by endoscopist in light of the results of this own evaluation and of the Ai system output. The confidence level (high vs. low) in polyp characterization is recorded. The combined evaluation is compared with histopathology results.

Outcome Measures

Primary Outcome Measures

  1. Agreement of combined prediction with PIVI I statement [6 months]

    To prospectively evaluate whether the evaluation of the endoscopist combined with the CAD system output achieve > 90% accuracy in characterization (i.e. as adenomas or non-adenomas) of diminutive rectosigmoid polyps (i.e. PIVI I threshold) having histopathology as reference standard.

Secondary Outcome Measures

  1. Endoscopist prediction [6 months]

    to calculate the performance measures (sensitivity, specificity, positive and negative predictive value) of the endoscopist alone in characterizing diminutive rectosigmoid polyps

  2. Ai prediction [6 months]

    - to calculate the performance measures (sensitivity, specificity, positive and negative predictive value) of the AI system alone in characterizing diminutive rectosigmoid polyps

  3. Agreement of combined prediction with PIVI II statement [6 months]

    - to evaluate if the evaluation of the endoscopist combined with the CAD system output achieve > 90% accuracy in the assignment of post-polypectomy surveillance intervals, according to US and EU guidelines, when combined with the histopathology assessment of polyps >5 mm in size

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Consecutive adult outpatients undergoing elective colonoscopy, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected.
Exclusion Criteria:
  • patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer

  • patients with inadequate bowel preparation

  • patients scheduled for partial examinations

  • polyps could not be resected due to ongoing anticoagulation preventing resection and pathologic assessment

  • patients undergoing urgent colonoscopy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Gastroenterology Unit, Valduce Hospital Como Italy 22100

Sponsors and Collaborators

  • Valduce Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Franco Radaelli, Head of Gastroenterology Unit, Valduce Hospital
ClinicalTrials.gov Identifier:
NCT04607083
Other Study ID Numbers:
  • 599/2020
First Posted:
Oct 28, 2020
Last Update Posted:
Jun 10, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 10, 2021